Last reviewed · How we verify

Pipracil (Piperacillin Sodium)

Pfizer Inc. · FDA-approved approved Small molecule Quality 65/100

Piperacillin and tazobactam is an antibacterial drug combination.

Piperacillin and tazobactam is a combination penicillin-class antibacterial with beta-lactamase inhibitor indicated for multiple serious infections in adults and pediatric patients 2 months and older. The drug demonstrates time-dependent pharmacodynamics with short half-lives and approximately 30% protein binding. Significant drug interactions exist with aminoglycosides, probenecid, vancomycin, anticoagulants, and neuromuscular blockers requiring monitoring or separate administration. Use should be reserved for proven or strongly suspected bacterial infections to prevent resistance development.

At a glance

Generic namePiperacillin Sodium
SponsorPfizer Inc.
Drug classPenicillin-class antibacterial with beta-lactamase inhibitor
TargetBeta-lactamase producing bacteria
ModalitySmall molecule
PhaseFDA-approved
First approval1981

Mechanism of action

Piperacillin is a penicillin-class antibacterial agent combined with tazobactam, a beta-lactamase inhibitor. The pharmacodynamic parameter most predictive of clinical and microbiological efficacy is time above MIC (minimum inhibitory concentration). This combination is designed to overcome beta-lactamase resistance mechanisms in susceptible bacterial pathogens.

Approved indications

Boxed warnings

Common side effects

Drug interactions

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
FDA Orange BookPatents + exclusivity

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: